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Discussion
Dr Yoshiya Toyoda (Pittsburgh, Pa). What do you think is the
mechanism of the difference in outcome between daclizumab and
AT, because previously we have shown there is no difference in
AR and survival between daclizumab and AT, and alemtuzumab
induction is much better in terms of AR. Are there any differences
in, for example, pulmonary protection or preservation protocols
for infection, prophylaxis, or ventilatory management?
Dr Ailawadi. Those are good questions. The question is basi-
cally to try to elucidate why we saw these differences between the
AT group and the daclizumab group. Primarily, what we saw with
our patients receiving AT was that they got very sick, and few pa-
tients were able to tolerate the full course of AT induction. Patients
receiving daclizumab were all able to tolerate the full treatment
courses, as long as they survived, as most of them did.
As to why AR, BOS, and survival would all have similar out-
comes dependent on induction, what we see is that of all patients
who had AR, 46% went on to have BOS, and approximately 42%
of patients that had BOS died during the study period. So these three
outcomes are clearly linked. Our hope is that if we can prevent the
first insult, AR, we may be able to interfere with later outcomes.
Dr Toyoda. Have you checked T-cell or B-cell counts to, for
example, 6 months? With alemtuzumab induction, those are signif-
icantly less. That can explain this AR.
Dr Ailawadi. We do not routinely check T or B cell counts.
Dr Toyoda. Then you changed your lung preservation or protec-
tion protocol?
DrAilawadi. There were no differences. We used the same pres-
ervation agent during the study period.
Dr Mark J. Krasna (Towson, Md). Just to follow up that last
question, during this long period, were there any other changes in
technique? Obviously, you talked about the maturation of the pro-
gram. I assume that if you looked at the number of cases per year,
it probably increased in the later years. Were there any changes in
technique that might have had significance?
Dr Ailawadi. We really looked hard for any differences, and we
did not find anything concrete that was different. Our volumes
increased slightly during the study period, ranging from 16 trans-
plants per year in the AT era to 20 transplants per year in the dacli-
zumab era.
Dr Bansi Koul (Lund, Sweden). I was wondering about these
two series conducted over time. How about patients with, say,
HLA antibodies? How are you managing those patients, or did
you exclude those from this study?
DrAilawadi.We routinely used these induction agents in all our
patients. So we did not exclude any patients because of HLA anti-
bodies.
Dr Koul. So you are confident in using daclizumab for patients
who have a high percentage of antibodies in the blood, without any
monitoring for them in the early postoperative period?
Dr Ailawadi. We monitor them for clinical outcomes. We used
daclizumab for all patients, even those with high antibody levels.
Shu S. Lin (Durham, NC). I congratulate you for presenting
such a clear study. I do have one question; during your analysis
did you find any difference in the number of biopsies obtained in
the two eras?
Dr Ailawadi. That is a good question. We have not looked at
that, and it would be interesting to know the number of patients
who underwent diagnosis by various criteria, whether pathologic
or clinical criteria.
DrKrasna. Just one other question perhaps you could clarify for
us. You obviously have some ideas about why you see the difference
in AR in those patients with chronic obstructive pulmonary disease,
something that you have never heard before, or why this is only the
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second time we have heard a relationship with sarcoid and BOS. Do
you want to give us a supposition on your part or what your impres-
sion is?
Dr Ailawadi. As for the chronic obstructive pulmonary disease,
I don’t have a good explanation. With regard to the sarcoid, it obvi-
ously is a different disease process, and there is probably some auto-
immune process going on. The study to which I referred is actually out
of Pittsburgh in 1999. It studied a very small group of patients and, as
a matter of fact, didn’t reach statistical significance, but patients who
underwent transplantation for sarcoid had an incidence of BOS of
50%, significantly greater than their experience with other diagnoses.
Dr Gus J. Vlahakes (Boston, Ma). In what model is the daclizu-
mab produced? How is it made? Is it made in a murine model?
Dr Ailawadi. It is a recombinant antibody.
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